Consensus Amgen Inc. Xetra

Stocks

AMG

US0311621009

Pharmaceuticals

Real-time Estimate Tradegate 12:18:26 01/10/26 am AEST			5-day change	1st Jan Change
372.30 ^EUR	+1.21%		+4.41%	+33.00%

29/09	Scotiabank Raises Amgen Price Target to $500 From $450, Sector Outperform Rating Kept	MT
26/09	Mesirow Financial Investment Management, Inc. acquired office complex in Deerfield from Amgen Inc. (NasdaqGS : AMGN) for $151 million.	CI

2af07f85cd826.bJyRidIlzJHRsr2PSSe7W_AmaJI2BqM19g7AhrRyX4c.W9ip27l0p_yAhOnnOkz5CpVqPN5hY-VyqV-L1PAqKL5BqPS6u2-h2ITj3g~d1c2776f7a91b199498beb33af59aa25

Analysts' recommendations: Amgen Inc.

29/09	Scotiabank Raises Amgen Price Target to $500 From $450, Sector Outperform Rating Kept	MT
23/09	Jefferies Adjusts Amgen Price Target to $410 From $367, Maintains Hold Rating	MT
10/09	HSBC Downgrades Amgen to Hold From Buy, Adjusts Price Target to $425 From $445	MT
09/09	Amgen's Olpasiran May Still Show Heart-Risk Reduction Despite Novartis Miss, UBS Says	MT
08/09	Rothschild & Co Redburn Adjusts Price Target on Amgen to $225 From $235, Keeps Sell Rating	MT
08/09	BMO Capital Downgrades Amgen to Market Perform From Outperform, Price Target is $450	MT
08/09	Analyst recommendations: Amgen, Equifax, Lockheed Martin, Phillips 66, Valero Energy…
07/09	Analyst recommendations: Amgen, Broadcom, Lululemon, Palo Alto Networks…
04/09	Wells Fargo Adjusts Price Target on Amgen to $435 From $400, Keeps Equalweight Rating	MT
20/08	Piper Sandler Adjusts Price Target on Amgen to $457 From $427, Maintains Overweight Rating	MT
19/08	Argus Research Adjusts Amgen Price Target to $460 From $375, Maintains Buy Rating	MT
19/08	Morgan Stanley Adjusts Price Target on Amgen to $362 From $351, Keeps Equalweight Rating	MT
18/08	Mizuho Adjusts Price Target on Amgen to $352 From $303, Maintains Neutral Rating	MT
18/08	Cantor Fitzgerald Adjusts Price Target on Amgen to $400 From $350, Maintains Neutral Rating	MT
18/08	Mizuho Securities Adjusts Amgen Price Target to $352 From $303	MT
13/08	Daiwa Securities Adjusts Price Target on Amgen to $430 From $390, Keeps Outperform Rating	MT
13/08	Barclays Adjusts Price Target on Amgen to $380 From $360, Maintains Equalweight Rating	MT
10/08	HSBC Adjusts Price Target on Amgen to $445 From $425, Keeps Buy Rating	MT
07/08	Citigroup Adjusts Price Target on Amgen to $405 From $345, Maintains Neutral Rating	MT
07/08	Rothschild & Co Redburn Adjusts Amgen Price Target to $235 From $220, Maintains Sell Rating	MT
05/08	Bernstein Adjusts Price Target on Amgen to $345 From $335, Maintains Market Perform Rating	MT
05/08	UBS Adjusts Price Target on Amgen to $440 From $420, Maintains Buy Rating	MT
05/08	JPMorgan Adjusts Price Target on Amgen to $350 From $300, Maintains Neutral Rating	MT
05/08	Wells Fargo Adjusts Price Target on Amgen to $400 From $390, Maintains Equalweight Rating	MT
05/08	Leerink Partners Adjusts Price Target on Amgen to $395 From $355, Maintains Market Perform Rating	MT

More recommendations

Other Pharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ELI LILLY AND COMPANY					+12.17%
	JOHNSON & JOHNSON					+4.37%
	ABBVIE INC.					+5.91%
	MERCK & CO., INC.					+4.29%
	ROCHE HOLDING AG					+7.46%
	NOVARTIS AG					+5.11%
	ASTRAZENECA PLC					+28.35%
	AMGEN INC.					-7.72%
	GILEAD SCIENCES, INC.					+4.87%
	Average					+7.20%
	Weighted average by Cap.					+7.93%